Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

Channels

Screener

Funds

Advisors

Advisor Access

News

What Johnson & Johnson's Earnings Mean for Mutual Fund Investors (JNJ)

Shauna O'Brien Jan 20, 2015

Before the opening bell on Tuesday, Johnson & Johnson (JNJ) released its fourth quarter financial results. Here’s what the report means for mutual fund investors.

JNJ’s Q4 Results

Earnings

JNJ reported earnings of $2.52 billion, or 89 cents per share, down from $3.52 billion, or $1.23 per share, a year ago. Excluding special items, earnings were $3.6 billion, or $1.27 per share – above analysts’ expectation of $1.24 per share.

Revenue
Revenue came in at $18.25 billion, down from $18.36 billion last year. Analysts expected to see revenue of $18.59 billion.

Outlook
Looking ahead, JNJ expects to see FY2015 between $6.12 and $6.27 per share. Analysts are expecting earnings of $6.13 per share.

JNJ to be Impacted by the Stronger Dollar

Despite Johnson & Johnson’s Q1 profit beat, the near-term could be a bit volatile with the stronger dollar acting as an overhang for the company’s profit upside. The stock is trading at just 17x 2015 earnings estimates and is fairly priced.

The stock currently has a dividend yield of about 2.7%, which may be attractive to income-focused investors.

Mutual Funds to Watch

Investors interested in JNJ may be interested in the funds listed below. These funds currently have the largest stakes in the company.

Symbol	Mutual Fund	Stake
VTSMX	Vanguard Total Stock Market	1.68%
VFINX	Vanguard 500 Index	1.08%
FCNTX	Fidelity® Contrafund®	0.68%

The Bottom Line

The funds listed above allow investors to gain exposure to JNJ while remaining diversified. Investors interested in JNJ may also be interested in Pfizer (PFE) and Merck (MRK).